Skip to main content
BIOVENTIX PLC logo

BIOVENTIX PLC — Investor Relations & Filings

Ticker · BVXP ISIN · GB00B4QVDF07 LEI · 213800225MHX7LZQY108 IL Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2023-09-19 Major Shareholding Noti…
Country GB United Kingdom
Listing IL BVXP

About BIOVENTIX PLC

https://www.bioventix.com/

Bioventix PLC is a biotechnology company that specializes in the development, creation, and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized by global diagnostic companies as critical components in clinical diagnostic platforms, particularly for blood testing immunoassays. The company's portfolio supports a variety of applications, including diagnostics for cardiovascular conditions (troponin), oncology, and neurodegenerative diseases such as Alzheimer's. In addition to its core antibody products, Bioventix also provides ELISA kits for monitoring exposure to industrial pollutants and offers contract services for the development of new SMAs for healthcare organizations.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is clearly identified by the header 'RNS Number : 9597M' and contains the standard format 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The content details the percentage change (from 16.96% to 14.45%) and the date the threshold was crossed (18 September 2023). This fits the definition for Major Shareholding Notification (MRQ).
2023-09-19 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. It details changes in voting rights percentages (crossing thresholds) held by a shareholder (SANFORD DELAND ASSET MANAGEMENT LTD) in the issuer (BioVentix PLC). This structure and content perfectly match the definition of a Major Shareholding Notification, which is classified under the code MRQ.
2023-07-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. It details the acquisition or disposal of voting rights, specifying the shareholder (SANFORD DELAND ASSET MANAGEMENT LTD), the issuer (BioVentix PLC), the date the threshold was crossed (06 June 2023), and the resulting percentage of voting rights (17.91%). This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized under the code MRQ.
2023-07-06 English
Board Appointment
Board/Management Information Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number: 8774A) from BioVentix PLC. The core content announces the appointment of a new independent Non-Executive Director, Joanne Pisani, to the Board. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. Although it is distributed via RNS, the specific subject matter is not general regulatory news but a specific management change, making MANG the most precise classification. The document length (4107 chars) is substantial enough to be the primary announcement, not just a link to one.
2023-05-30 English
Director/PDMR Shareholdings and Issue of Equity
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details 'Director/PDMR Shareholdings and Issue of Equity', specifically reporting transactions by a Director (Ian Nicholson) involving the exercise of options and subsequent sale of shares, along with an announcement regarding the admission of new ordinary shares. This type of mandatory disclosure regarding insider transactions (PDMR dealings) and minor capital changes, distributed via the Regulatory News Service (RNS), strongly points to a regulatory filing. While it contains elements of Director's Dealing (DIRS) and Share Issue (SHA), the overall format and distribution mechanism (RNS) make it a general regulatory announcement. Since 'Director's Dealing' (DIRS) is a specific category for reporting personal share transactions by directors, and this document is primarily focused on that, DIRS is the most appropriate specific classification over the general RNS fallback, although RNS is also highly relevant due to the distribution source.
2023-05-19 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document explicitly announces 'Director Dealing' concerning the Chief Financial Officer, Bruce Hiscock, purchasing company shares. It details the transaction, including price, volume, and date, and includes a formal notification structure required under the EU Market Abuse Regulation. This directly corresponds to the definition of 'Director's Dealing' (Code: DIRS). The document is short and appears to be a regulatory filing announcement, but the content is specific enough to classify it as DIRS rather than the general RNS fallback.
2023-04-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.